NHS’s breakthrough leukaemia therapy set to transform lives in UK
Clinical trials found that 77% of patients went into remission after receiving obe-cel
Clinical trials found that 77% of patients went into remission after receiving obe-cel
The European Commission’s green light marks Breyanzi’s fourth indication in Europe and extends access to patients across all EU and EEA countries
This is the first and only subcutaneous immune checkpoint inhibitor available in Europe
The collaboration to develop breakthrough myeloid cell engagers (MCEs) signals a bold push into a promising new frontier in cancer therapy
This is the first drug to receive a recommendation for this preventative indication in the European Union
The modular platform not only targets solid tumors but could also enhance traditional autologous and in vivo T cell therapies
Fenebrutinib targets cells in the immune system known as B cells and microglia
Sepsis is a life-threatening reaction to infection that overwhelms the body’s defenses
Novartis is the only pharmaceutical company with a dedicated commercial RLT portfolio
Subscribe To Our Newsletter & Stay Updated